Quarterly and annual results disclosed under 8-K Item 2.02.
FENNEC PHARMACEUTICALS INC. reported the fourth quarter of 2025 results: revenue $13.8 million.
“For the fourth quarter of 2025, the Company recorded net product sales of $13.8 million compared to $7.9 million in the fourth quarter of 2024, representing an increase of approximately 75%.”
FENNEC PHARMACEUTICALS INC. reported the fiscal year ended December 31, 2025 results: revenue approximately $44.6 million.
“For the full fiscal year (FY) 2025, the Company recorded net product sales of approximately $44.6 million compared to $29.6 million in 2024, representing an increase of approximately 50%.”
MAXCYTE, INC. reported full year 2026 results: revenue Expects 2026 revenue of $30-32 million. Guidance initiated.
“Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million”
MAXCYTE, INC. reported fourth quarter ended December 31, 2025 results: revenue total revenue of $7.3 million, net income net loss was $9.6 million.
“Total revenue for the fourth quarter of 2025 was $7.3 million, compared to $8.7 million in the fourth quarter of 2024, representing a decrease of 16%.”
GameStop Corp. reported fiscal year ended January 31, 2026 results: revenue $3.630 billion, net income $418.4 million.
“at the close of the prior year's fourth quarter. • Bitcoin and related receivables were valued at $368.4 million at the close of the quarter. FULL YEAR OVERVIEW • Net sales were $3.630 billion for fiscal year 2025, compared to $3.823 billion in fiscal year 2024. • SG&A expenses were $910.2 million for fiscal year 2025, compared to $1.130 billion in fiscal year 2024. •”
GameStop Corp. reported fourth quarter ended January 31, 2026 results: revenue $1.104 billion, net income $127.9 million.
“and non-GAAP results, are below. The Company’s Form 10-K and supplemental information can be found at https://investor.gamestop.com . FOURTH QUARTER OVERVIEW • Net sales were $1.104 billion for the fourth quarter, compared to $1.283 billion in the prior year's fourth quarter. • Selling, general and administrative (“SG&A”) expenses were $241.5 million for the fourth”
Neurogene Inc. reported twelve months ended December 31, 2025 results: net income -90.4 million.
“Full Year 2025 Financial Results • Cash, Cash Equivalents and Short-Term Investments : Cash, cash equivalents and short-term investments as of December 31, 2025 were $269.0 million and are expected to fund planned operations through the first quarter of 2028. • Research & Development (R&D) Expenses : R&D expenses were $75.0 million for the twelve months ended December 31, 2025, compared to $60.9 million for the twelve months ended December 31, 2024. The increase in R&D expenses for the twelve months ended December 31, 2025 was primarily driven by an increase in Rett syndrome clinical trial costs and employee-related expenses due to an increase in R&D headcount, and it was partially offset by decreases in spending on the CLN5 Batten disease program and early discovery. • General & Administrative (G&A) Expenses : G&A expenses were $28.3 million for the twelve months ended December 31, 2025, compared to $22.6 million for the twelve months ended December 31, 2024. The increase in G&A expen”
Leatt Corp reported financial results for the fourth quarter and full year ending December 31, 2025.
“On March 24, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.”
Paysign, Inc. reported fourth quarter 2025 results: revenue total revenues of $22.76 million, net income net income of $1.36 million, EPS $0.02 per diluted share.
“Fourth quarter 2025 total revenues of $22.76 million, up 45.8% from fourth quarter 2024”
Paysign, Inc. reported full-year 2025 results: net income net income of $7.55 million.
“Full-year 2025 total revenues of $82.0 million, up 40.5% from 2024”
TELA Bio, Inc. reported financial results for the fourth quarter of 2025 and the fiscal year ended December 31, 2025.
“On March 24, 2026, TELA Bio, Inc. (the " Company ") issued a press release announcing its financial results for the fourth quarter of 2025 and the fiscal year ended December 31, 2025.”
Bright Mountain Media, Inc. reported the year ended December 31, 2025 results: revenue $59.2 million, net income net loss was $13.5 million.
“Revenue was $59.2 million, an increase of $2.5 million, or 4%, compared to $56.7 million for the same period of 2024.”
Bright Mountain Media, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $15.7 million, net income net loss was $3.3 million.
“Revenue was $15.7 million, a decrease of $1.4 million, or 8%, compared to $17.1 million for the same period of 2024.”
FRACTYL HEALTH, INC. updated its quarter and full year ended December 31, 2025 guidance (reaffirmed).
“On March 24, 2026, Fractyl Health, Inc. (the “Company”) announced its financial results for the quarter and full year ended December 31, 2025 and provided a corporate update.”
Absci Corp reported the quarter and full year ended December 31, 2025 results: revenue $0.7 million for the three months ended December 31, 2025 compared to $0.7 million for the three months ended December 3.
“On March 24, 2026, Absci Corporation (the “Company”) announced its financial results for the fourth quarter ended December 31, 2025.”
Braze, Inc. reported the fiscal year ended January 31, 2026 results: revenue $738.2 million, net income GAAP net loss per share attributable to Braze common stockholders, basic and diluted, of $1.22, EPS $1.22.
“Revenue was $738.2 million compared to $593.4 million in the fiscal year ended January 31, 2025, up 24.4% year-over year, driven primarily by new customers, upsells, and renewals.”
Braze, Inc. reported the quarter ended January 31, 2026 results: revenue $205.2 million, net income GAAP net loss per share attributable to Braze common stockholders, basic and diluted, of $0.29, EPS $0.29.
“Revenue was $205.2 million compared to $160.4 million in the fourth quarter of the fiscal year ended January 31, 2025, up 27.9% year-over year, driven primarily by new customers, upsells, and renewals.”
AAR CORP reported the fiscal year 2026 third quarter ended February 28, 2026 results: revenue $845.1 million, net income $68.0 million, EPS $1.71 per diluted share. Guidance raised.
“reported today financial results for the fiscal year 2026 third quarter ended February 28, 2026. THIRD QUARTER FISCAL YEAR 2026 HIGHLIGHTS (As compared to Q3 FY2025) · Sales of $845 million; increased 25% · GAAP diluted EPS of $1.71 · Adjusted diluted EPS of $1.25; increased 26% · GAAP Net income of $68 million · Adjusted EBITDA of $102 million; increased 26% ·”
Concentrix Corp reported first quarter ended February 28, 2026 results: revenue $2,500.4 million, net income $21.6 million, EPS $0.33. Guidance reaffirmed.
“accompanying financial tables for the reconciliation of each non-GAAP measure to its most directly comparable GAAP measure. First Quarter Fiscal 2026 Highlights: • Revenue of $2,500.4 million, an increase of 5.4% year-on-year on an as reported basis compared to revenue of $2,372.2 million in the prior year first quarter. The Company grew revenue 1.9% year-on-year on a”
LENZ Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $1.6 million.
“and Recent Corporate Highlights Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals”
COMPASS Pathways plc reported financial results for the year ended December 31, 2025.
“Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth quarter and full-year 2025 financial results and business highlights.”
Velo3D, Inc. reported the twelve months ended December 31, 2025 results: revenue $46.0, net income ($71.4), EPS ($4.33) per share - basic and diluted. Guidance raised.
“require for mission-critical applications." ($ in Millions, except percentages and per-share data) 4th Quarter 2025 4th Quarter 2024 FY 2025 FY 2024 GAAP revenue $9.4 $12.6 $46.0 $41.0 GAAP gross margin (73.6)% (3.5)% (16.1)% (5.1)% GAAP net loss 1 ($21.9) ($21.3) ($71.4) ($69.9) GAAP net loss per share - basic and diluted ($1.03) ($12.37) ($4.33) ($82.46)”
Velo3D, Inc. reported the three and twelve months ended December 31, 2025 results: revenue $9.4, net income ($21.9), EPS ($1.03) per share - basic and diluted. Guidance raised.
“our customers require for mission-critical applications." ($ in Millions, except percentages and per-share data) 4th Quarter 2025 4th Quarter 2024 FY 2025 FY 2024 GAAP revenue $9.4 $12.6 $46.0 $41.0 GAAP gross margin (73.6)% (3.5)% (16.1)% (5.1)% GAAP net loss 1 ($21.9) ($21.3) ($71.4) ($69.9) GAAP net loss per share - basic and diluted ($1.03) ($12.37)”
Biomea Fusion, Inc. reported the year ended December 31, 2024 results: net income net loss of $138.4 million.
“The Company reported a net loss attributable to common stockholders of $61.8 million for the year ended December 31, 2025, which included $9.5 million of stock-based compensation, compared to a net loss of $138.4 million for the same period in 2024, which included $19.1 million of stock-based compensation.”
Biomea Fusion, Inc. reported the full year ended December 31, 2025 results: net income net loss of $61.8 million.
“Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the full year ended December 31, 2025 and provided a business update.”
Core & Main, Inc. reported fourth quarter and fiscal year ended February 1, 2026 results: revenue $1,581 million, net income $73 million, EPS $0.37.
“quarter and fiscal year ended February 2, 2025 ("fiscal 2024"). Fiscal 2025 Fourth Quarter Results (Compared with Fiscal 2024 Fourth Quarter) • Net sales decreased 6.9% to $1,581 million; Average daily net sales increased 0.9% • Gross profit margin increased 50 bps to 27.1% • Net income increased 9.0% to $73 million • Diluted earnings per share increased 12.1% to”
Blaize Holdings, Inc. reported the quarter and year ended December 31, 2025 results: revenue $38.6 million.
“AI infrastructure increasingly centers on inference-driven systems, enabled by efficiency-focused architectures designed for real-world AI deployment. In 2025, Blaize delivered $38.6 million in revenue, up from $1.6 million in 2024, marking its first full year of commercial revenue generation. This was driven by expanding engagements with system integrators and”
Hour Loop, Inc reported the year ended December 31, 2025 results: revenue $142.4 million, net income $1.7 million, EPS $0.05 per diluted share. Guidance initiated.
“a leading online retailer, announces its financial and operational results for the year ended December 31, 2025. Financial Highlights for 2025: ● Net revenues increased 3% to $142.4 million, compared to $138.3 million in the year-ago period; ● Net income increased to $1.7 million, compared to $0.7 million in the year-ago period; and ● Cash provided by operating”
M-tron Industries, Inc. reported financial results for the fiscal year ended December 31, 2025.
“On March 24, 2026, M-tron Industries, Inc. ("Mtron" or the "Company") reported its financial results for the fourth quarter and full fiscal year ended December 31, 2025. A copy of the press release containing this information is furnished as Exhibit 99.1 hereto and is incorporated by reference in this Item 2.02.”
M-tron Industries, Inc. reported financial results for the three months ended December 31, 2025.
“On March 24, 2026, M-tron Industries, Inc. ("Mtron" or the "Company") reported its financial results for the fourth quarter and full fiscal year ended December 31, 2025. A copy of the press release containing this information is furnished as Exhibit 99.1 hereto and is incorporated by reference in this Item 2.02.”
Sanara MedTech Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $27.5 million, net income Net loss from continuing operations of $1.1 million. Guidance reaffirmed.
“December 31, 2025, and reaffirmed its financial guidance for the full year ending December 31, 2026. Fourth Quarter 2025 Financial Summary (1 ) ● Net revenue increased 5% to $27.5 million, compared to $26.3 million in the fourth quarter of 2024. ○ As previously disclosed, the Company experienced growth in sales of BIASURGE ® Advanced Surgical Solution”
INTRUSION INC reported full year ended December 31, 2025 results: revenue $7.1 million, net income ($9.1) million, EPS $(0.46) per share.
“Revenue for the full year ended December 31, 2025, was $7.1 million, an increase of $1.3 million or 23% compared to 2024.”
INTRUSION INC reported fourth quarter ended December 31, 2025 results: revenue approximately $1.5 million, net income ($2.8) million, EPS $(0.14) per share.
“Revenue for the fourth quarter of 2025 was approximately $1.5 million, representing a decrease of 12% on a year-over-year basis.”
KB HOME reported three months ended February 28, 2026 results: revenue $1.08 billion, net income $33.4 million, EPS $.52. Guidance initiated.
“Relations Contact (310) 893-7456 or jpeters@kbhome.com Cara Kane, Media Contact (321) 299-6844 or ckane@kbhome.com KB HOME REPORTS 2026 FIRST QUARTER RESULTS Revenues of $1.08 Billion; Diluted Earnings Per Share of $.52 Repurchased $50.0 Million of Common Stock LOS ANGELES (March 24, 2026) — KB Home (NYSE: KBH) today reported results for its first quarter”
SMITHFIELD FOODS INC reported fourth quarter ended December 28, 2025 results: revenue $4.2 billion, EPS $0.83.
“Fourth Quarter Fiscal 2025 Financial Highlights • Net sales of $4.2 billion, up 7.0% from the fourth quarter of 2024”
SMITHFIELD FOODS INC reported fiscal year ended December 28, 2025 results: revenue $15.5 billion, EPS $2.51.
“meats and fresh pork, today reported results for its fiscal 2025 fourth quarter and year ended December 28, 2025. Full Year Fiscal 2025 Financial Highlights • Net sales of $15.5 billion, up 9.8% from fiscal year 2024 • Operating profit of $1,292 million, up 15.6% from fiscal year 2024; Adjusted operating profit of $1,336 million, up 30.5% from fiscal year 2024 •”
ENERGY FOCUS, INC/DE reported financial results for the fourth quarter ended December 31, 2025.
“announced financial results for its fourth quarter and fiscal year ended December 31, 2025”
ENERGY FOCUS, INC/DE reported the fiscal year ended December 31, 2025 results: revenue $3.6 million, net income $1.0 million, EPS $(0.18) per basic and diluted share.
“Full-Year 2025 and Subsequent Business Highlights • Net sales of $3.6 million, down 26.7% from 2024, reflecting a decrease of 42.7% in MMM sales and an increase of 10.5% in commercial sales.”
SMITH MIDLAND CORP reported the fourth quarter and full year 2025 ended December 31, 2025 results: revenue $22 to $24 million, net income higher versus the fourth quarter of 2024.
“For the fourth quarter of 2025, the Company expects revenues of approximately $22 to $24 million, compared to $18.5 million in the prior-year comparable quarter, primarily due to higher product sales and shipping and installation revenue. The Company also anticipates net income to be higher versus the fourth quarter of 2024.”
BioCardia, Inc. reported financial results for the year ended December 31, 2025.
“On March 24, 2026, BioCardia, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.”
ACHIEVE LIFE SCIENCES, INC. reported the fourth quarter and full year ended December 31, 2025 results: net income Total net loss for the three and twelve months ended December 31, 2025, was $14.7 million and $54.7 million, respectivel.
“On March 24, 2026, Achieve Life Sciences, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.”
UNITED STATES ANTIMONY CORP reported financial results for fiscal year 2025.
“On March 19, 2026, United States Antimony Corporation (“USAC”, “US Antimony,” or the “Company”) held a conference call to discuss the Company’s financial and operational results for fiscal year 2025. A recorded replay of the presentation is available on the Company’s website at https://www.usantimony.com/investors until April 2, 2026. A written transcript of this conference call is being furnished by the Company on this Current Report as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 2.02 disclosure.”
BATTALION OIL CORP reported the fourth quarter of 2025 results: revenue $32.3 million, net income net loss available to common stockholders of $12.5 million, EPS net loss of $0.76 per share.
“Executive Officer of Battalion. Results of Operations Average daily net production and total operating revenue during the fourth quarter of 2025 were 11,207 Boe/d (48% oil) and $32.3 million, respectively, as compared to production and revenue of 12,750 Boe/d 1 (55% oil) and $49.7 million, respectively, during the fourth quarter of 2024. The decrease in revenues in”
SUTRO BIOPHARMA, INC. reported financial results for the full year 2025.
“On March 23, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.”
TALPHERA, INC. reported the three and twelve months ended December 31, 2025 results: net income Net loss attributable to common shareholders for the fourth quarter of 2025 was $3.8 million, or $0.06 per basic and dil, EPS $0.06 per basic and diluted share. Guidance initiated.
“On March 23, 2026, Talphera, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2025 and providing a corporate update (the “Release”).”
Arbutus Biopharma Corp reported the fourth quarter and year ended December 31, 2025 results: revenue $14.1 million.
“one-time payments related to its restructuring efforts. This was partially offset by $5.5 million of proceeds from the exercise of stock options. Revenue Total revenue was $14.1 million for the year ended December 31, 2025, compared to $6.2 million for the same period in 2024. The increase of $7.9 million was due to the recognition of all previously-deferred”
Avalo Therapeutics, Inc. reported the year ended December 31, 2025 results: net income Net loss was $78.3 million for the year ended December 31, 2025, EPS Basic and diluted net loss per share was $5.84 for the year-ended December 31, 2025.
“On March 23, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.”
Lument Finance Trust, Inc. reported fourth quarter and fiscal year ended December 31, 2025 results: net income GAAP net loss attributable to common shareholders for the fourth quarter was $(8.9) million, or $(0.17) per share of com, EPS $(0.17) per share of common stock (fourth quarter), $(0.14) per share of common stock (full year).
“Lument Finance Trust Reports 2025 Results NEW YORK, March 23, 2026 /PRNewswire/ — Lument Finance Trust, Inc. (NYSE: LFT) (“we”, “LFT” or “the Company”) today reported its fourth quarter and full year 2025 results. GAAP net loss attributable to common shareholders for the fourth quarter was $(8.9) million, or $(0.17) per share of common stock, and for the full year was $(7.5) million, or $(0.14) per share of common stock.”
Ondas Inc. updated its the fourth quarter and full year ended December 31, 2025 guidance (raised).
“On March 23, 2026, Ondas Inc. issued a press release announcing its financial and operating results for the fourth quarter and full year ended December 31, 2025.”
Cabaletta Bio, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 23, 2026, Cabaletta Bio, Inc. (the "Company") announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.